Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Neuroblastoma 6Sarcoma, Ewing 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Medulloblastoma 2Glioma 2Glioblastoma 2Astrocytoma 2Typical Teratoid Rhabdoid Tumor 1Rhabdoid Tumor 1Prostatic Neoplasms 1Osteosarcoma Recurrent 1Oligodendroglioma 1Non-melanoma Skin Cancer 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Temozolomide 12Vincristine 9Irinotecan 8Cyclophosphamide 8cabozantinib 6X-Rays 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Etoposide 5regorafenib 4fludarabine 4Radiotherapy 4Phantoms, Imaging 4Ifosfamide 4Doxorubicin 4Radiation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2liposomal doxorubicin 2ivosidenib 2irinotecan sucrosofate 2etoposide phosphate 2abemaciclib 2Zoledronic Acid 2Topotecan 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Eflornithine × 1 year × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡